Glenmark launches Teneligliptin+Dapagliflozin Fixed-Dose Combination for adults with type-II diabetes

Glenmark Pharma has launched Teneligliptin (20mg) + Dapagliflozin (5mg/10mg) Fixed-Dose Combination (FDC) for the treatment of adult patients with type-II diabetes, especially the ones with comorbidities, a company statement notified.

Marketed under the brand name Zita D, it contains Teneligliptin (20mg)+Dapagliflozin (5 mg/10 mg), and must be taken once daily under prescription to improve glycemic control and prevent complications in adult patients with type-II diabetes, especially the ones with comorbidities , the statement added.